Member Info for Vascular

Hi PR. Like you , i still can't access the platform holding yesterday's talk, so gave up ...and watched previous half year one. Tom states clearly several contracts,waiting to be signed and seems to be dependent once tension od Electoral Fund decision, which gas now been made. .....so we should expect at least two wins, maybe more over weeksor month ahead IMO.

Thanks Rebarm. I'll give it a go.. I looked on FDBKs web page thinking that would be an obvious place to post it for future reference but not there yet.

Hi Rebarm, That's the link i used, several times . I completed the form and sent it off and received a email reply which i posted here....and never received the link to the presentation. I even emailed the HSJ using their help email which is returned a message that email is dead , also posted here.

It was not a criticism of a presentation i was not allowed to access but a criticism of a S&*t platform that FDBK .

Why don't they use InvestorMeet, which i was using this afternoon for another compony presentation, Scancell.

Its not a good look for a company selling digital communication pathways! I'll get over it, but new investors may think differently. They need to be able to at least communicate with its iinvestors.

Looks like it's fingers crossed for a 2pm RNS !

Well I have given up , i hope its just me for FDBKs sake. I have had several of these emails but no link.

"Feedback Medical Webinar Confirmation

Thank you for registering for this webinar.

This webinar is brought to you in partnership with Feedback Medical.

You will receive another email from Swapcard with information on how to access the platform and view the webinar. If you have any queries or need any further information in the meantime, please get in touch at eventssupport@hsj.co.uk."

Any feedback from todays presentation would be appreciated. Cheers V

Anyone else finding it difficult to join todays presentation via #HSJModernisingDiagnostics !!

I have enrolled three times over past few days, and sent them a message via their help email twice asking for enrolment and received the following reply.

"The given E-Mail address "eventssupport@hsj.co.uk." is invalid.

any other way to join!!

Cheers Vas

It looks like to me that with a lack of any share activity the mms just do what they want within the spread ( currently 6%) to try and get some interest - they don't care if its a buy or a sell. Just a trade to them.

What we want is not just good news, but good news with legs, demonstrating further good news coming down the line at some point. This will add confidence and further buying at Todays share price.

"For example, we tend to think of the NHS App as some interesting side event, whereas actually it could be the fulcrum of an entirely different operating model for the NHS, where we utilise digital pathways much more and empower people to manage their own health.........The digital health record will enable us to have these new models of care, like if you want to extend Pharmacy First, or have integrated neighbourhood teams.

You can’t have Boots thinking they’re managing your blood pressure over here and your GP thinking they’re managing it over there, and each working on two different records.

You can’t have integrated neighbourhood teams where social workers are going in one day and health visitors the next, and then a GP, and they’re not working off the same record. They’re clearly not a team unless they’re using the same record...We need a digital health record to keep all that information together in one place.

OneLondon, Manchester and the other shared care records go some way to delivering the properties of a digital health record, but there are things that they don’t do.

For example, I may be able to review my health records through the NHS App, but I can’t then share them with trusted third parties to help me manage my COPD or diabetes or blood pressure.

If we want to be able to use more of these services, you need something pulling it all together. It is completely critical to changing the operating model of the NHS.

Worth a red as i believe they are talking about a solution which is ( to a greater degree) offered by FDBK.

https://www.digitalhealth.net/2025/03/charlotte-refsum-digital-health-records-are-critical-to-changing-the-nhs/

The last fund raise of approx £5.5 m , was last Nov 24 and at 44p, the average share price at that time.

Roll on six months and the evidence for FDBKs opportunity has changed significantly for the better with not only Tom still talking the talk, but other health professionals also, and hospitals but Importantly the UK government.

Here we are at 18p with so much possibility clearly being evidenced to us online and on TV that new Digital solutions will be required by the NHS, and soon.

Toms reference on his half year presentation about linking with chemists is IMO very important .

Here is the Briefing 010/25: Funding Settlement for 2024/25 and 2025/26 Community Pharmacy England, the Department of Health and Social Care (DHSC) and NHS England have announced the 2024/25 and 2025/26 funding settlement for community pharmacy. This briefing outlines the key elements of the settlement.

"Service developments and changes to fees Pharmacy First Fees for the Minor Illness and Clinical Pathway consultations part of Pharmacy First are being uplifted to £17, whilst the Urgent Medicine Supply fee will remain at £15. In the negotiations, we were successful in gaining agreement to moving to a banded approach for the Pharmacy First monthly payment: £500 for those delivering 20-29 consultations per Community Pharmacy England cpe.org.uk month and £1,000 for those that achieve 30 or more. "

Its the beginning of community pharmacists being refereed non urgent patients, and there use of digital pathway as they consult and refer on to specialist, if required - so the relive waiting lists and hospital visits.

The high street chemists will eventually be part of the digital glue that TOM talks about in his presentation and also named two high street brands ( which surprised me) Boots and Superdrug.

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cpe.org.uk/wp-content/uploads/2025/03/Briefing-010.25-Funding-Settlement-for-2024-25-and-2025-26.pdf

GL Vas

Https://www.newindianexpress.com/nation/2025/Mar/24/india-expands-intensified-tb-elimination-campaign-nationwide

Sep 2024 07:00

RNS Number : 7696E

Feedback PLC

19 September 2024

Feedback signs collaboration agreement with a provider of primary care solutions

Love to have an update on this mystery partner!

“ Feedback plc ("Feedback" or the "Company"), has signed a collaboration agreement with a provider of primary care solutions to explore the opportunities for a novel Neighborhood Diagnostics Solution.….. The collaboration provides a route to rapidly scale the Bleepa solution and pathway approach, leveraging the existing footprint of the party….. The Company estimates that over 190m diagnostic tests per year could be redirected to a pharmacy setting. If taken to a national scale this opportunity could represent an estimated total addressable market of £382m annually with further opportunities for potential international expansion. Commercial revenue from this potential opportunity remains subject to, inter alia, successful pilots and commercial agreement between the parties.”

https://www.lse.co.uk/rns/FDBK/collaboration-agreement-2sm4lz9gow35xiq.html

Sorry, should read..

Interesting the name used in this article / initiative is exactly the same ....

Interesting the name used gkirvthis initiative iscrxactky the same name used by FDBK in Nov 24 in this article

Changing the sequence: Diagnostic Enhanced Advice & Guidance   !!

https://feedbackmedical.com/feedback-medical/changing-the-sequence-diagnostic-enhanced-advice-guidance/

Looks like Moorehouse where awarded ten months ago ( along with others) some very large contracts one for £500,000,000 and another for £12,350,000,000 both titles Digital Health Advisory

The framework includes:

Lot 1 - Specialist Clinical and Healthcare Digital Consultancy

Lot 2 - Clinical and Digital Health Delivery and Augmentation

Lot 3 - Clinical Data Science & Population Health Analytics

Lot 4 - Digital Skills in Healthcare

https://intelapp.io/explore/organisations/981520b6-35b9-4387-91f3-d658aebeafaa/moorhouse-consulting-limited?supplies=3

Six months later entered a strategic partnership with FDBK Medical.

Coincidence. Maybe , Maybe not. Should find out the product of this alliance sometime soon, I think.

Moorehouse won a one year consultancy contract in Feb 25 with SURREY AND BORDERS PARTNERSHIP NHS FOUNDATION TRUST

fDBK announced in Oct 24 about a new Strategic partnership with this implementation partner

“ Description

a variety of management consultancy services as part of a call off contract up to an agreed contract value. These services are likely to include (but not exclusive to): • AI and digital technology advisory • Functional and governance reviews • Financial improvement support • Embedding change in relation to digital technology and AI

Award Detail

1 Moorhouse Consulting (None)

Value: £750,000

https://bidstats.uk/tenders/2025/W14/843842119

You never know ……

Sorry, info below announced below in October 24, not Jan 25

Hi Dalester.

Looks like the PFS , at 80% is at 6 months on 30th Jan 2025.

“ SCIB1, a DNA cancer vaccine, reported compelling positive interim data in the ongoing SCOPE study

for Advanced Melanoma, as follows:

o 80% Progression Free Survival (PFS) in 25 patients at 6 months with 20% of patients

achieving a complete response (CR).

o Disease control rate of 84% (stable disease or tumour regression, DCR) and objective

response rate (ORR) of 72%.”

https://scancell.co.uk/wp-content/uploads/2025/01/Scancell-Interim-Results-31-October-2024.pdf

“ Data due to be presented at the American Association for Cancer Research (AACR) meeting later this month in 25 patients will show an 84% disease control rate, 80% progression-free survival (PFS) with a 20% complete response rate, and a 72% objective response rate.”

https://pharmaphorum.com/news/scancell-taps-nhs-matchmaking-service-cancer-trial

84% Disease control rate :

Disease control rate (DCR) in clinical trials measures the percentage of patients whose disease has been controlled, meaning it has either completely gone away, partially shrunk, or remained stable for a certain period. It's a key indicator of a treatment's effectiveness.

80% progression free survival:

PFS is the length of time a patient lives with the disease, but it doesn't get worse or spread to other parts of the body.

How it's used:

PFS is a common endpoint in clinical trials to assess the effectiveness of new cancer treatments. It helps researchers understand how well a treatment is controlling the cancer.

72% objective response rate.

ORR is calculated by determining the proportion of patients in a study group who achieve either a complete response (CR), where all signs of cancer are gone, or a partial response (PR), where the tumor size decreases by a certain percentage (usually 30% or more).

Why it's important:

ORR provides a quantifiable measure of treatment efficacy, allowing researchers to compare the effectiveness of different treatments and to determine if a new treatment is significantly better than existing ones.

And still in development 😊

I think the issue about the Elective Care cap being scrapped is confirmed at least until up until 2026 but what I would like to see / find evidence for is that these uncapped payments will continue to be rolled out for a significant number of years after year end 26. I am sure commissioners in the NHS and suppliers would also like confirmation so to have confidence that new services / pathways etc put in this year can continue and expand in the years that follow. Anyone found any reference to the present uncapped elective care budgets continuing on a rolling basis after 2026. They may well continue and be revised yearly . Confirmation imo would be a green light .GL vas